Tag: Maytansine
Stable, Site-Specific ADC Conjugation with SMARTag® Technology and Innovative Linker
Antibody-drug conjugates have achieved commercial success over the last 10 years with 15 therapies launched globally to date, including 11 with U.S. FDA approval, and two biosimilars. With their ability to direct highly potent cytotoxic payloads selectively to target cells, ADCs offer the prospect of more precise treatments and a reduction in off-target effects.
ASH 2020: Positive Interim Phase I Study Results of TRPH-222 in...
TRPH-222 (CD22-4AP), an antibody-drug conjugate (ADC) being developed by Triphase, demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients...
Are Small-Format Drug Conjugates a Viable ADC Alternative Solid Tumors?
Antibody-drug conjugates or ADCs are complex immunoconjugates. They are designed to selectively deliver a small-molecules cytotoxic payload to cancer cells. Directed to specific tumor...
New ADC Payload Platform – Synaffix Launches toxSYN™
The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...
